
    
      The primary efficacy objective of this study is to assess whether patients with severe,
      moderate, or complicated mild TBI administered RP-1127 will show a decrease in MRI-defined
      edema and/or hemorrhage, compared to patients administered placebo.

      The primary safety objective is to assess the safety and tolerability of RP-1127 compared to
      placebo in patients with severe, moderate, or complicated mild TBI.
    
  